Sample size is too low but very encouraging.
The 83% headline is a bit misleading but only a tiny bit. If we do like for like comparison of 'completed' outcomes:
78% on sample size 9 is still amazing though but even thinner for my liking.
Surer numbers will come out after the full 240 patient trial comes out (Announced 9th April)
From a purely stat point of view, seeing how likely these kind of results are, we have to consider the whole population, including those who are still hospitalized.
Using the same data, the results are a bit less impressive.
IHD%R ² î R5õ IDATxÜÝÙ³fÉqöü¶»ßÞ§gzv@¬A‚@€»C|#
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-481
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.25 |
Change
-0.060(2.60%) |
Mkt cap ! $2.931B | |||
| Open | High | Low | Value | Volume |
| $2.32 | $2.39 | $2.24 | $10.30M | 4.449M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 38292 | $2.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.25 | 31466 | 16 |
View Market Depth
| Last trade - 13.57pm 22/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |